Baker Bros. Advisors as of Sept. 30, 2015
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 133 positions in its portfolio as reported in the September 2015 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Incyte Corporation (INCY) | 19.9 | $2.1B | 20M | 110.33 | |
Seattle Genetics | 12.8 | $1.4B | 36M | 38.56 | |
Alexion Pharmaceuticals | 9.4 | $1.0B | 6.5M | 156.39 | |
Abbvie (ABBV) | 7.2 | $782M | 14M | 54.41 | |
ACADIA Pharmaceuticals (ACAD) | 6.3 | $677M | 21M | 33.07 | |
Incyte Corp Ltd conv | 5.5 | $598M | 275M | 2.18 | |
Incyte Corp Incy Cvt 144a 0.37 convert | 5.2 | $559M | 259M | 2.16 | |
Anacor Pharmaceuticals In | 4.5 | $487M | 4.1M | 117.71 | |
BioMarin Pharmaceutical (BMRN) | 4.0 | $429M | 4.1M | 105.32 | |
Genomic Health | 2.7 | $289M | 14M | 21.16 | |
Clovis Oncology Inc note 2.500% 9/1 | 2.0 | $216M | 129M | 1.67 | |
Dbv Technologies S A | 1.8 | $194M | 5.5M | 35.59 | |
BioCryst Pharmaceuticals (BCRX) | 1.5 | $161M | 14M | 11.40 | |
Dyax | 1.3 | $144M | 7.6M | 19.09 | |
Biomarin Pharmaceutical Inc note 1.875% 4/2 | 1.1 | $116M | 22M | 5.17 | |
Mirati Therapeutics | 0.9 | $102M | 3.0M | 34.42 | |
Aquinox Pharmaceuticals | 0.9 | $95M | 6.7M | 14.07 | |
Gilead Sciences conv | 0.8 | $90M | 21M | 4.31 | |
Heron Therapeutics (HRTX) | 0.7 | $71M | 2.9M | 24.40 | |
Cerus Corporation (CERS) | 0.6 | $62M | 14M | 4.54 | |
Bellicum Pharma | 0.6 | $61M | 4.2M | 14.53 | |
Acorda Therap note 1.75% 6/15 | 0.5 | $54M | 60M | 0.91 | |
Spark Therapeutics | 0.5 | $53M | 1.3M | 41.73 | |
Invitae (NVTAQ) | 0.4 | $47M | 6.6M | 7.22 | |
Versartis | 0.3 | $37M | 3.2M | 11.53 | |
ImmunoGen | 0.3 | $34M | 3.5M | 9.60 | |
Neurocrine Biosciences (NBIX) | 0.3 | $30M | 751k | 39.79 | |
Acorda Therapeutics | 0.3 | $29M | 1.1M | 26.51 | |
Insmed (INSM) | 0.3 | $29M | 1.6M | 18.57 | |
Medivation | 0.3 | $28M | 660k | 42.50 | |
Halozyme Therapeutics (HALO) | 0.2 | $26M | 1.9M | 13.43 | |
Gilead Sciences (GILD) | 0.2 | $25M | 250k | 98.19 | |
Progenics Pharmaceuticals | 0.2 | $25M | 4.4M | 5.72 | |
Intra Cellular Therapies (ITCI) | 0.2 | $24M | 609k | 40.04 | |
Idera Pharmaceuticals | 0.2 | $23M | 7.0M | 3.35 | |
Exelixis Inc cnv | 0.2 | $24M | 20M | 1.20 | |
Zogenix | 0.2 | $24M | 1.8M | 13.50 | |
Atyr Pharma Inc Common Stock Usd 0.001 | 0.2 | $24M | 2.3M | 10.26 | |
XenoPort | 0.2 | $23M | 6.5M | 3.47 | |
Sangamo Biosciences (SGMO) | 0.2 | $21M | 3.8M | 5.64 | |
Catalyst Pharmaceutical Partners (CPRX) | 0.2 | $22M | 7.3M | 3.00 | |
Tg Therapeutics (TGTX) | 0.2 | $20M | 2.0M | 10.08 | |
Array BioPharma | 0.2 | $20M | 4.3M | 4.56 | |
Aegerion Pharmaceuticals 2% Du cvbond | 0.2 | $20M | 27M | 0.75 | |
Clovis Oncology | 0.2 | $19M | 203k | 91.96 | |
Alder Biopharmaceuticals | 0.2 | $17M | 513k | 32.76 | |
Derma Sciences | 0.1 | $16M | 3.5M | 4.71 | |
Biomarin Pharmaceutical Inc note 0.750%10/1 | 0.1 | $16M | 12M | 1.30 | |
Novavax | 0.1 | $16M | 2.2M | 7.07 | |
Foamix Pharmaceuticals | 0.1 | $15M | 2.0M | 7.33 | |
Galapagos Nv- (GLPG) | 0.1 | $15M | 369k | 40.71 | |
Achillion Pharmaceuticals | 0.1 | $14M | 2.0M | 6.91 | |
Repros Therapeutics | 0.1 | $15M | 2.0M | 7.43 | |
Proqr Thrapeutics N V shs euro (PRQR) | 0.1 | $14M | 988k | 14.57 | |
Zafgen | 0.1 | $13M | 390k | 31.95 | |
Threshold Pharmaceuticals | 0.1 | $12M | 2.9M | 4.07 | |
Bluebird Bio (BLUE) | 0.1 | $12M | 141k | 85.55 | |
La Jolla Pharmaceuticl Com Par | 0.1 | $11M | 412k | 27.79 | |
Ultragenyx Pharmaceutical (RARE) | 0.1 | $12M | 124k | 96.31 | |
Xencor (XNCR) | 0.1 | $11M | 872k | 12.23 | |
Lion Biotechnologies | 0.1 | $11M | 1.8M | 5.76 | |
Osiris Therapeutics | 0.1 | $9.2M | 499k | 18.47 | |
Alcobra | 0.1 | $9.9M | 1.6M | 6.04 | |
Concert Pharmaceuticals I equity | 0.1 | $9.3M | 496k | 18.77 | |
Akari Therapeutics | 0.1 | $9.5M | 396k | 23.99 | |
Global Blood Therapeutics In | 0.1 | $8.4M | 200k | 42.16 | |
Agios Pharmaceuticals (AGIO) | 0.1 | $7.1M | 100k | 70.59 | |
Macrogenics (MGNX) | 0.1 | $7.4M | 348k | 21.42 | |
Ascendis Pharma A S (ASND) | 0.1 | $7.7M | 436k | 17.70 | |
Ligand Pharmaceuticals In (LGND) | 0.1 | $6.3M | 73k | 85.66 | |
Endocyte | 0.1 | $6.2M | 1.4M | 4.58 | |
Neuroderm Ltd F | 0.1 | $6.3M | 305k | 20.67 | |
Dermira | 0.1 | $6.4M | 275k | 23.34 | |
Aimmune Therapeutics | 0.1 | $6.3M | 250k | 25.32 | |
Arrowhead Research | 0.1 | $5.8M | 1.0M | 5.76 | |
Aerie Pharmaceuticals | 0.1 | $5.3M | 299k | 17.74 | |
Ignyta | 0.1 | $5.0M | 571k | 8.78 | |
Curis | 0.0 | $4.0M | 2.0M | 2.02 | |
Amarin Corporation (AMRN) | 0.0 | $4.3M | 2.2M | 1.93 | |
Chimerix (CMRX) | 0.0 | $4.4M | 115k | 38.20 | |
Trevena | 0.0 | $4.7M | 450k | 10.35 | |
Sage Therapeutics (SAGE) | 0.0 | $4.4M | 105k | 42.32 | |
Proteon Therapeutics | 0.0 | $3.8M | 275k | 13.91 | |
Pronai Therapeutics | 0.0 | $4.1M | 200k | 20.52 | |
Omeros Corporation (OMER) | 0.0 | $3.7M | 336k | 10.96 | |
Cytrx | 0.0 | $3.1M | 1.3M | 2.37 | |
Enanta Pharmaceuticals (ENTA) | 0.0 | $2.7M | 75k | 36.13 | |
Mast Therapeutics | 0.0 | $2.7M | 4.7M | 0.58 | |
D Stemline Therapeutics | 0.0 | $2.9M | 334k | 8.83 | |
Epizyme | 0.0 | $3.0M | 233k | 12.86 | |
Array Biopharma Inc note 3.000% 6/0 | 0.0 | $2.9M | 3.0M | 0.97 | |
Juno Therapeutics | 0.0 | $3.3M | 80k | 40.69 | |
Seres Therapeutics (MCRB) | 0.0 | $3.7M | 125k | 29.64 | |
Natera (NTRA) | 0.0 | $2.7M | 250k | 10.85 | |
Nabriva Therapeutics | 0.0 | $3.3M | 350k | 9.50 | |
ISIS Pharmaceuticals | 0.0 | $2.3M | 57k | 40.43 | |
Ironwood Pharmaceuticals (IRWD) | 0.0 | $1.8M | 169k | 10.42 | |
Palatin Technologies | 0.0 | $1.7M | 2.1M | 0.81 | |
Sunesis Pharmaceuticals | 0.0 | $2.6M | 3.2M | 0.81 | |
Karyopharm Therapeutics (KPTI) | 0.0 | $2.3M | 217k | 10.53 | |
Mediwound Ltd cmn | 0.0 | $1.7M | 225k | 7.63 | |
Vitae Pharmaceuticals | 0.0 | $2.1M | 188k | 11.01 | |
Immune Design | 0.0 | $1.8M | 149k | 12.20 | |
Loxo Oncology | 0.0 | $1.7M | 100k | 17.48 | |
Aurinia Pharmaceuticals (AUPH) | 0.0 | $2.0M | 712k | 2.81 | |
Marinus Pharmaceuticals | 0.0 | $1.7M | 200k | 8.34 | |
Assembly Biosciences | 0.0 | $2.4M | 250k | 9.56 | |
Affimed Therapeutics B V | 0.0 | $2.5M | 400k | 6.17 | |
Dynavax Technologies (DVAX) | 0.0 | $1.8M | 75k | 24.55 | |
Protalix Biotherapeutics Inc note 4.500% 9/1 | 0.0 | $2.5M | 3.4M | 0.72 | |
Bellerophon Therapeutics | 0.0 | $1.8M | 353k | 5.19 | |
Alnylam Pharmaceuticals (ALNY) | 0.0 | $911k | 11k | 80.34 | |
BioDelivery Sciences International | 0.0 | $1.2M | 210k | 5.56 | |
Discovery Laboratories | 0.0 | $1.1M | 3.6M | 0.30 | |
Ohr Pharmaceutical | 0.0 | $1.0M | 370k | 2.76 | |
Acceleron Pharma | 0.0 | $716k | 29k | 24.89 | |
Ophthotech | 0.0 | $1.4M | 36k | 40.51 | |
Achaogen | 0.0 | $576k | 100k | 5.76 | |
Uniqure Nv (QURE) | 0.0 | $614k | 30k | 20.47 | |
Aldeyra Therapeutics (ALDX) | 0.0 | $828k | 142k | 5.83 | |
Tenax Therapeutics | 0.0 | $1.3M | 420k | 3.00 | |
Trillium Therapeutics, Inc. Cmn | 0.0 | $821k | 63k | 13.03 | |
Cellectis S A (CLLS) | 0.0 | $1.3M | 50k | 26.36 | |
Adaptimmune Therapeutics (ADAP) | 0.0 | $1.2M | 100k | 11.97 | |
Arbutus Biopharma (ABUS) | 0.0 | $1.1M | 181k | 6.09 | |
Ritter Pharmaceuticals | 0.0 | $820k | 400k | 2.05 | |
Cyclacel Pharmaceuticals Inc pfd conv ex 6% (CYCCP) | 0.0 | $62k | 13k | 4.68 | |
Synergy Pharmaceuticals | 0.0 | $356k | 67k | 5.31 | |
Chemocentryx | 0.0 | $297k | 49k | 6.05 | |
Foundation Medicine | 0.0 | $385k | 21k | 18.43 | |
Five Prime Therapeutics | 0.0 | $296k | 19k | 15.38 | |
Biotime Inc wts oct 1 18 | 0.0 | $17k | 20k | 0.85 | |
Aptose Biosciences | 0.0 | $144k | 33k | 4.31 |